Farrell M Ryan, Lawrenz Cedric W, Levine Laurence A
Department of Urology, Rush University Medical Center, Chicago, IL.
Department of Urology, Rush University Medical Center, Chicago, IL.
Urology. 2017 Dec;110:223-227. doi: 10.1016/j.urology.2017.07.017. Epub 2017 Jul 20.
To describe our experience with direct visual internal urethrotomy (DVIU) and mitomycin C (MMC) for recurrent bulbar and bulbomembranous urethral strictures of radiation and non-radiation-induced etiologies.
We reviewed our database of consecutive patients presenting to our tertiary care institution with recurrent bulbar and bulbomembranous urethral strictures who underwent DVIU with MMC from 2011 to 2016. Patients were stratified by radiation-induced strictures (RIS) vs non-RIS. Cold-knife incisions were made at 12-, 3-, and 9-o'clock positions followed by intralesional injection of 10 mL MMC (0.4 mg/mL) in 0.2-0.4 mL aliquots and 1 month of postoperative daily clean intermittent catheterization (CIC).
All 44 patients (RIS n = 18, non-RIS n = 26) failed prior endoscopic management or urethroplasty. Median stricture length was 2.0 cm (interquartile range [IQR] 1.0-2.5). Over a median follow-up of 25.8 months (IQR 12.9-47.2), 75.0% of patients (33/44) required no additional surgical intervention (RIS 12/18, 66.7%; non-RIS 21/26, 80.8%). Median time to stricture recurrence among those who recurred was 10.7 months (IQR 3.9-17.6; RIS 9.4 months, IQR 3.5-17.6; non-RIS 11.2 months, IQR 8.0-25.6). Four patients (RIS n = 2, non-RIS n = 2) elected to undergo urethroplasty for recurrence. A second DVIU with MMC was performed in the remaining recurrences (n = 7) with no further surgical intervention required in 37 of 40 of patients (92.5%) overall (RIS 14/16, 87.5%; non-RIS 23/24, 95.8%). No long-term complications were attributable to MMC.
DVIU with MMC and short-term CIC for recurrent, short, bulbar and bulbomembranous urethral strictures is a safe endoscopic modality with promising early results. This approach may be useful for patients who are suboptimal candidates for open reconstruction.
描述我们使用直视下尿道内切开术(DVIU)和丝裂霉素C(MMC)治疗放射性和非放射性病因引起的复发性球部及球膜部尿道狭窄的经验。
我们回顾了2011年至2016年期间在我们三级医疗机构就诊的因复发性球部及球膜部尿道狭窄而接受DVIU联合MMC治疗的连续患者数据库。患者按放射性狭窄(RIS)和非RIS进行分层。在12点、3点和9点位置进行冷刀切开,然后在病变内注射10 mL MMC(0.4 mg/mL),每次注射0.2 - 0.4 mL,术后每日进行1个月的清洁间歇性导尿(CIC)。
所有44例患者(RIS组18例,非RIS组26例)先前的内镜治疗或尿道成形术均失败。狭窄的中位长度为2.0 cm(四分位间距[IQR] 1.0 - 2.5)。中位随访25.8个月(IQR 12.9 - 47.2),75.0%的患者(33/44)无需额外的手术干预(RIS组12/18,66.7%;非RIS组21/26,80.8%)。复发患者狭窄复发时间的中位数为10.7个月(IQR 3.9 - 17.6;RIS组9.4个月,IQR 3.5 - 17.6;非RIS组11.2个月,IQR 8.0 - 25.6)。4例患者(RIS组2例,非RIS组2例)因复发选择接受尿道成形术。其余复发患者(n = 7)接受了第二次DVIU联合MMC治疗,总体40例患者中有37例(92.5%)无需进一步手术干预(RIS组14/16,87.5%;非RIS组23/24,95.8%)。没有长期并发症可归因于MMC。
DVIU联合MMC及短期CIC治疗复发性、短段的球部及球膜部尿道狭窄是一种安全的内镜治疗方法,早期效果良好。这种方法可能对开放重建手术不太理想的患者有用。